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OnOBJECTIVES The purpose of this study was to assess the phenotype of Filamin C (FLNC) truncating variants in dilated
cardiomyopathy (DCM) and understand the mechanism leading to an arrhythmogenic phenotype.
BACKGROUND Mutations in FLNC are known to lead to skeletal myopathies, which may have an associated cardiac
component. Recently, the clinical spectrum of FLNC mutations has been recognized to include a cardiac-restricted
presentation in the absence of skeletal muscle involvement.
METHODS A population of 319 U.S. and European DCM cardiomyopathy families was evaluated using whole-exome and
targeted next-generation sequencing. FLNC truncation probands were identiﬁed and evaluated by clinical examination,
histology, transmission electron microscopy, and immunohistochemistry.
RESULTS A total of 13 individuals in 7 families (2.2%) were found to harbor 6 different FLNC truncation variants
(2 stopgain, 1 frameshift, and 3 splicing). Of the 13 FLNC truncation carriers, 11 (85%) had either ventricular arrhythmias
or sudden cardiac death, and 5 (38%) presented with evidence of right ventricular dilation. Pathology analysis of 2
explanted hearts from affected FLNC truncation carriers showed interstitial ﬁbrosis in the right ventricle and epicardial
ﬁbrofatty inﬁltration in the left ventricle. Ultrastructural ﬁndings included occasional disarray of Z-discs within the
sarcomere. Immunohistochemistry showed normal plakoglobin signal at cell–cell junctions, but decreased signals for
desmoplakin and synapse-associated protein 97 in the myocardium and buccal mucosa.
CONCLUSIONS We found FLNC truncating variants, present in 2.2% of DCM families, to be associated with a
cardiac-restricted arrhythmogenic DCM phenotype characterized by a high risk of life-threatening ventricular
arrhythmias and a pathological cellular phenotype partially overlapping with arrhythmogenic right ventricular
cardiomyopathy. (J Am Coll Cardiol EP 2018;4:504–14) © 2018 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2405-500X https://doi.org/10.1016/j.jacep.2017.12.003
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505AB BR E V I A T I O N S
AND ACRONYM S
Cx43 = connexin 43
DCM = dilated cardiomyopathy
DNA = deoxyribonucleic acid
ExAC = Exome Aggregation
Consortium
FLNC = Filamin C
SK3b = glycogen synthase
kinase 3 beta
HCM = hypertrophic
cardiomyopathy
LV = left ventricle/ventricular
MFM = myoﬁbrillar skeletal
myopathy
RNA = ribonucleic acidD ilated cardiomyopathy (DCM) is a majorcause of heart failure and disproportion-ately leads to cardiac transplantation (1–3).
The condition is familial in w50% of cases, and ge-
netic variants residing in over 40 genes have been
found to cause DCM through a variety of pathological
mechanisms associated with perturbations of the
cytoskeleton, intercalated disc region, nuclear enve-
lope, and muscle sarcomere (1,3). Filamin C (FLNC)
is an actin cross-linking protein (4) that provides
structure for the sarcomere and is one of the largest
Z-disc proteins (2,725 amino acids) in cardiac and
skeletal muscle. FLNC also localizes to the sarco-
lemma, where it connects the muscle cell to the extra-
cellular matrix and is involved in related signaling
pathways (5).SEE PAGE 515 RV = right ventricle/ventricular
SAP97 = synapse-associated
protein 97
SCD = sudden cardiac death
TEM = transmission electron
microscopyOriginally, FLNC gene mutations were associated
with distal and myoﬁbrillar skeletal myopathies
(MFM) (6), characterized by loss of myoﬁbrils and
ﬁlamentous intracellular aggregates of myocyte pro-
teins, including desmin, dystrophin, and sarcogly-
cans. Further investigations have revealed that FLNC
missense mutations may lead to hypertrophic cardio-
myopathy (HCM) (7) and restrictive cardiomyopathy
(RCM) (8). Recently, using whole exome sequencing,
we identiﬁed an FLNC splicing variant as causing DCM
in the absence of skeletal muscle involvement in 2
families (9), a ﬁnding further supported by the report
of FLNC truncation variants in 4% of DCM and 3% of
arrhythmogenic DCM patients (10–12).
In the current study, we report the characterization
of the clinical features of FLNC truncating variant
carriers, which include a prominent arrhythmogenic
DCM phenotype (13), sarcomere structural changes by
transmission electron microscopy (TEM), and changes
in the distribution of cell–cell junction proteins in the
myocardium and buccal mucosa. These structural and
cellular changes overlap with arrhythmogenic rightUniversity Hospital S. Maria della Misericordia, Udine, Italy; fDepartment o
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represent a critical link between DCM and
ARVC, leading to a more comprehensive un-
derstanding of complex familial arrhythmia
syndromes as well as an appreciation of the
need for mutation-directed clinical moni-
toring and treatment of this population.
METHODS
STUDY POPULATION AND CARDIOMYOPATHY
EVALUATION. We analyzed 319 U.S. and
European DCM families from the Familial
Cardiomyopathy Registry. Study subjects
underwent extensive clinical evaluations
(details in the Online Appendix) (14). Medical
records from deceased subjects were
reviewed when available (9). Informed con-
sent was obtained from living subjects, and
local institutional review boards approved
the study protocols.
NEXT-GENERATION SEQUENCING AND
BIOINFORMATIC ANALYSIS. Twenty larger
families were evaluated by whole-exome sequencing
(9). In 299 smaller families, probands were evaluated
using the Illumina TruSight One-Sequence panel
(Illumina, Redwood City, California), which queries
4,813 genes associated with known clinical pheno-
types (15). Brieﬂy, subject deoxyribonucleic acid
(DNA) was captured with the panel, sequenced on an
HISEQ 2500 (Illumina) with v4 chemistry, and map-
ped with Genomic Short-read Nucleotide Alignment
Program (version 2012-07-20) (16). Variants were
called with the Genome Analysis Toolkit (version 2.1-
8-g5efb575, Broad Institute, Cambridge, Massachu-
setts) and classiﬁed with Annovar (version 2012-07-
28) (17). Functional predictions were made with the
database for Nonsynonymous SNPs and Their Func-
tional Predictions (version 2.0) (18). All variants were
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FIGURE 1 Pedigrees of DCM Families With FLNC Truncating Variants Displaying an Arrhythmogenic Phenotype
(A) Squares indicate males, circles indicate females, slashes indicate deceased individuals, black shading indicates a dilated cardiomyopathy
(DCM) phenotype, and vertical lines indicate history of heart disease. The arrows indicate the proband. Carriers (þ) and noncarriers () of a
FLNC truncation variant are shown. (B) Electrocardiogram of subject TSSDC130 (II:3) shows sustained ventricular tachycardia. (C) Electro-
cardiogram depicts nonsustained ventricular tachycardia from individual II:1 (family DNFDC057) (9).
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506predicted to be damaging in at least 1 of the predic-
tion algorithms were retained, whereas missense and
truncation variants present in >1% in the 1000 Ge-
nomes Project were discarded (9,20).
Variant frequency information was obtained from
the 6,500 National Human, Lung, and Blood Institute
Exome Sequencing Project (21) and the Exome
Aggregation Consortium (ExAC, Cambridge, Massa-
chusetts) (22) on February 27, 2017, and wascross-referenced to the ClinVar database (23).
Gene variant locations are provided in reference to
FLNC transcript NM_001458. Cosegregation analysis
was performed when DNA from biological relatives
was available. Variants in other cardiomyopathy-
related genes were also identiﬁed using the Illumina
TruSight One Sequencing Panel, as described in
the previous text, and conﬁrmed using Sanger
sequencing.
FIGURE 2 Structural Distribution of Truncating Variants in the Human FLNC Protein
Schematic of the FLNC immunoglobulin-like repeats labeled 1 to 24 using transcript NP_001449.3. Hinge 1 and 2 domains are labeled as H1 and H2, respectively.
Red vertical lines indicate protein positions of the 6 FLNC truncation variants detected in our dilated cardiomyopathy (DCM) families. Black vertical lines
represent previously reported hypertrophic cardiomyopathy (HCM) (7), restrictive cardiomyopathy (RCM) (8), DCM variants (12), and myoﬁbrillar skeletal myopathies
(MFM) (6) variants.
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507HISTOLOGY AND TRANSMISSION ELECTRON
MICROSCOPY. Cardiac muscle tissue was obtained
from 2 affected siblings of family DNFDC057 (Figure 1),
including left ventricular (LV) tissue at the time of LV
assist device placement in subject II:1 and LV and right
ventricular (RV) tissue from the explanted heart of
subject II:2. Fresh heart tissue samples were pro-
cessed according to standard histology protocols for
hematoxylin and eosin, Masson’s trichrome, and
immunohistochemistry staining and ﬁxed for TEM.
Details can be found in the Online Appendix.
IMMUNOSTAINING. Cotton-tipped swabs (Medi-
Choice, Mechanicsville, Virginia) were used to collect
buccal mucosa cells from 2 siblings with truncating
variants in FLNC and from normal control subjects.
Each cheek was rubbed with a slight rolling and
scraping motion, and the resulting material was
smeared on standard microscope slides. Immuno-
staining of buccal mucosa and myocardial tissue was
performed as previously described (24), and is detailed
in the Online Appendix. For immunoﬂuorescence mi-
croscopy, antibodies included: mouse monoclonal
antiplakoglobin (P8087, Sigma-Aldrich, St. Louis,
Missouri), mouse monoclonal anti–connexin 43 (Cx43)
(Millipore, Burlington, Massachusetts), mouse
monoclonal anti–N-cadherin (Sigma-Aldrich), mouse
monoclonal antidesmoplakin (Fitzgerald, Acton,
Massachusetts), mouse monoclonal anti–synapse-
associated protein 97SAP97 (Santa Cruz, Dallas,
Texas), and rabbit polyclonal antiglycogen synthase
kinase 3 b (GSK3b) (Cell Signaling Technology,
Danvers, Massachusetts). Immunostained prepara-
tions were analyzed by confocal microscopy (LSM-510,
Zeiss, Oberkochen, Germany).
RIBONUCLEIC ACID SEQUENCING OF EXPLANTED
HEART TISSUE. Ribonucleic acid (RNA) was extracted
from frozen LV tissue using the mirVana miRNAisolation kit (Thermo Fisher Scientiﬁc, Waltham,
Massachusetts) enriched for total RNA according to
manufacturer’s instructions with the exception of
replacing the lysis/binding buffer with mechanical
homogenization in TRIzol (Thermo Fisher Scientiﬁc).
The library was sequenced 1  50 (Illumina HiSeq
2500). Reads were ﬁltered for quality and aligned to
the GRCh37hg19 reference human genome using the
Genomic Short-read Nucleotide Alignment Program.
Transcripts aligning to FLNC were visualized using
the Integrative Genomics Viewer (Broad Institute).
RESULTS
IDENTIFICATION OF FLNC TRUNCATIONS. Patho-
genic/likely pathogenic variants have been identiﬁed
in approximately 40% of dilated cardiomyopathy
samples from the Familial Cardiomyopathy Registry
(data not shown), and include TTN (11%), sarcomeric
genes (10%), structural cytoskeleton genes (5%),
LMNA (4%), ion channel genes (2%), and other rare
genes (5%). A total of 6 FLNC truncation variants
(Figure 1), including 2 FLNC stopgain (families
DNFDC079 and TSSDC130), 1 frameshift (DNFDC057),
and 3 splicing variants (families DNFDC195,
TSFDC029, TSFDC031, and TSFDC043), were identi-
ﬁed in 7 of the 319 DCM families, for an overall fre-
quency of 2.2% (7 of 319) (Figure 2, Table 1), 100-fold
more frequent than the 0.02% FLNC loss of function
variants reported in ExAC (22). Five of the FLNC
truncation variants were absent from the 1000
Genomes Project, 6,500 Exome Sequencing Project,
ExAC, and ClinVar databases; c.805C>T had a minor
allele frequency of 8.3  106 in ExAC (Online
Table 1). FLNC variants p.Y2381Gfs21X and
p.G1891Vfs61X have been previously reported (9). The
6 FLNC truncation variants reported here (Figures 1
and 2) occur in the immunoglobulin domains of the
TABLE 1 Clinical Phenotype Features of FLNC Truncation Carriers and DCM-Affected Individuals
Family DNFDC057 DNFDC079 DNFDC195 TSFDC029
Individual II:1 II:2 III:1 II:2 II:2 III:4
Sex M F F M F F
Age at diagnosis, yrs 59 54 33 39 62 46
Variation Frameshift Stopgain Splicing Splicing
Nucleotide change c.5669-1delG c.2119C>T c.2930-1G>T c.7251þ1A>G
AA change p.G1891Vfs61X p.Q707X p.K977fs p.Y2381Gfs
Secondary mutation
NYHA functional class III II III II I II
Symptoms DOE, fatigue Palpitations, SOB Pre-syncope, SOB Syncope Palpitations Palpitations, SOB,
chest pain
Arrhythmias PACs, PVCs, NSVT PVCs, AF, sustained
VT (1997)
No arrhythmias Multiform PVCs Sustained VT, PVCs
(800/24 h), NSVT
PVCs (900/24h),
NSVT
ECG AVB1, incomplete
LBBB
AVB1, LVH Nonspeciﬁc ST
changes
PM, AICD, nonspeciﬁc
ST changes
PVCs Low voltages
LVEDD, cm 6.4 5.6 5.4 7.2 5.4, inferobasal
hypokinesis
5.5
LVEF, % 45 10 20 15 52 32
CK, U/l† 118 106 56 NA 56 32
RV Normal Mild dilatation Dilatation Mild dilatation and
dysfunction
Normal (FS 53%) Normal (FS 60%)
Outcome NYHA functional class
II, LVEF 21%, CRT,
AICD, LVAD (2016)
Severe LV and RV
dysfunction, heart
transplant (2009)
Normalized LVEF
60%
Appropriate AICD
discharge (2016)
NYHA functional
class I, LVEF 51%
NYHA functional
class II, NCD
Follow-up, yrs 11 11 1 6 15 14
TABLE 1 Continued
Family TSFDC029 TSFDC031 TSFDC043 TSSDC130
Individual III:6* III:7 IV:1 II:2 III:1 I:2 II:3
Sex M F M M M F M
Age at diagnosis, yrs 35 34 27 44 20 76 20
Variation Splicing Splicing Splicing Stopgain
Nucleotide change c.7251þ1A>G c.7251þ1A>G c.3791-1G>A c.805C>T
AA change p.Y2381Gfs p.Y2381Gfs p.G1264fs p.R269X
Secondary mutation SCN5A
c.5270delT; p.F1757fs
NYHA functional class I I II II I III II
Symptoms Asymptomatic, SCD Palpitations Fatigue, palpitations SOB Pre-syncope Fatigue, SOB Syncope
Arrhythmias NA No arrhythmias PACs, PVCs (93/24h) NSVT, couplet
(154/24h)
PAF, SVT, SAECG AF, frequent PVCs Sustained VT
ECG NA Normal RBBB Normal Normal AVB, RBBB, LAFB SB, IV conduction
delay, nonspeciﬁc
ST changes
LVEDD, cm NA 4.9 5.3 5.7 5.5, inferobasal
hypokinesis
6.4 6.9
LVEF, % NA 63 45 47 45 14 38
CK, U/l† NA 50 80 103 70 NA 130
RV NA Normal Normal NA Mild dilatation and
dysfunction (FS 33%)
Dilatation and
dysfunction
Normal
Outcome Cardiomegaly at
autopsy
NYHA
functional
class I
NYHA functional
class I, palpitations,
LVEF 52%
NYHA functional
class II, SCD
NYHA functional
class 1, palpitations,
LVEF 40%
PM, heart
failure death (2008)
Recurrent sustained
VT, AICD (1999),
NYHA functional
class II
Follow-up, yrs 15 15 4 17 9 14
Families DNFD057, TSFDC029, and TFDC031 are previously reported variants (9). *Individual III:6 died before enrollment; DNA was not available for genetic testing. †Normal CK level is <223 U/l.
AA ¼ amino acid; AF ¼ atrial ﬁbrillation; AICD ¼ automatic implantable cardioverter-deﬁbrillator; AVB ¼ atrioventricular block; CK ¼ creatine kinase; CRT ¼ cardiac resynchronization therapy, DOE ¼
dyspnea on exertion; ECG ¼ electrocardiogram; FS ¼ fractional shortening, IV ¼ intraventricular; LAFB ¼ left anterior fascicular block; LBBB ¼ left bundle branch block; LVAD ¼ left ventricular assist device;
LVEDD; left ventricular end-diastolic dimension; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; NA ¼ not available; NCD ¼ noncardiac death; NYHA ¼ New York Association
functional class; PAF ¼ paroxysmal atrial ﬁbrillation; PM ¼ pacemaker; PAC ¼ premature atrial contraction, PVC ¼ premature ventricular contraction; RBBB ¼ right bundle branch block; RV ¼ right ventricle;
SAECG ¼ signal-averaged electrocardiography; SB ¼ sinus bradycardia; SCD ¼ sudden cardiac death; SOB ¼ shortness of breath; ST ¼ sinus tachycardia; VT ¼ ventricular tachycardia.
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FIGURE 3 Cardiac Tissue Analysis of FLNC Truncation Variant Carrier From Family DNFDC057 (II:2)
(A) Trichrome staining of the left ventricle shows subepicardial interstitial and focal replacement ﬁbrosis and fatty inﬁltration (circle) in
areas containing degenerating cardiac myocytes. Scale bar ¼ 200 mm. (B) Fatty inﬁltration and mild ﬁbrosis are seen in the right ventricle.
Scale bar ¼ 100 mm.
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509FLNC protein with no apparent geographical clus-
tering or relationships to HCM, RCM, and MFM FLNC
variants described to date. The presence of a sec-
ondary “likely pathogenic” unique variant was found
in a known cardiomyopathy-related gene in the
TSFDC043 proband (SCN5A c.5270delT; p.F1757fs, not
reported in ExAC and ClinVar databases) who did not
show signs of Brugada or long QT syndromes. Finally,
FLNC missense variants detected in the overall pop-
ulation of 319 families are charted to the FLNC protein
in Online Figure 1 and details are reported in Online
Table 2.
RNA-Seq was performed on the explanted heart of
DNFDC057 patient II:2. The majority of FLNC tran-
scripts (141 of 162 total reads; 87.0%) were wildtype,
and the remaining reads predominantly contained
the c.5669-1delG, resulting in a frameshift and sub-
sequent premature stop codon (as nucleotide 5670 is
also a G, splicing occurs normally but introduces a
frameshift into exon 34). These data support a
mechanism of nonsense-mediated decay leading to
haploinsufﬁciency, consistent with our zebraﬁsh
studies in which morpholino knockdown of the ﬂncb
transcript led to a cardiac phenotype.
CLINICAL PHENOTYPES OF FLNC TRUNCATION
AFFECTED INDIVIDUALS. Clinical features of FLNC
truncation carriers are reported in Table 1, and a
detailed clinical description is reported in the
Online Appendix. None of the patients fulﬁlled Task
Force criteria of ARVC (25). Comprehensive physical
examination of the skeletal muscle of all probands
revealed no skeletal muscle abnormalities; serum
creatine kinase levels were normal in all tested
probands.Supraventricular and ventricular arrhythmias as
well as conduction disease were prominent clinical
features (Figure 1, Table 1). Ventricular arrhythmias
appear to originate from the LV or appeared poly-
morphic. Sudden cardiac death (SCD) occurred before
the age of 55 years in 5 of 22 (23%) conﬁrmed (n ¼ 13)
or suspected by family history (n ¼ 9) truncation
carriers. RV involvement with dilatation and/or
dysfunction was present in 5 of 13 (38%) cases. The
overall penetrance of FLNC truncation variants in our
7 families was 92% (1 unaffected of 13 total conﬁrmed
truncation carriers).
HISTOLOGICAL AND ULTRASTRUCTURAL CARDIAC
ANALYSIS OF FLNC G1891Vfs61X VARIANT. Cardiac
muscle tissue was studied from 2 affected siblings of
family DNFDC057. In the proband II:2, light micro-
scopic analysis of the LV from the explanted heart
showed myocyte hypertrophy, diffuse interstitial
ﬁbrosis, and focal replacement ﬁbrosis (Figure 3A).
Epicardial fat tissue inﬁltrated focally into the LV
myocardium, especially in areas of replacement
ﬁbrosis containing clusters of degenerating myocytes
with myoﬁbrillar loss (Figure 3A). The RV showed
increased interstitial ﬁbrosis and mild fatty inﬁltra-
tion (Figure 3B). In the affected sibling II:1, cardiac
tissue taken upon LV assist device placement showed
similar cardiac tissue pathology in the LV (Online
Figure 2).
Ultrastructural analysis of LV tissue of affected
patient II:1 (DNFDC057) using TEM (Figures 4A
and 4B) revealed largely normal sarcomere struc-
tures, although abnormal Z-discs were noted. In LV
tissue from individual II:2 and II:1 (DNFDC057), the
Z-discs appeared less compact and diffuse along the
FIGURE 4 Electron Microscopy Images of Left Ventricular Cardiac Muscle From Family DNFDC057
(A) Representative images from individual II:2 show disarrayed Z-discs (white arrows). (B) Magniﬁed image of the white box in A, showing a
thickened Z-disc pattern. (C and D) Representative TEM images from individual II:1 exhibiting disarray of Z-discs (black arrows). No aggregates
are seen in cardiac myocytes. Scale bars: (A) 1 mm, (B) 200 nm, (C and D) 1 mm.
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cases, no intracellular aggregates were seen.
IMMUNOHISTOCHEMICAL ANALYSIS OF FLNC AND
ARRHYTHMOGENIC-ASSOCIATED PROTEINS. Abnormal-
ities in the distribution and expression of desmo-
somal and gap junction proteins have been reported
in cardiac tissue of patients with arrhythmogenic
cardiomyopathy (26). Because some of the clinical
(SCD, ventricular arrhythmia) and structural (RV
involvement, ﬁbrofatty inﬁltration) features in our
FLNC patients mirrored features of arrhythmogenic
cardiomyopathy, we used immunohistochemistry to
characterize selected protein distribution in the LV
myocardial tissue in affected individual II:2 of family
DNFDC057 (Figure 5).
Immunohistochemistry staining for the desmo-
somal protein desmoplakin and SAP97, a membrane-
associated guanylate kinase involved in trafﬁcking
sodium and potassium channel subunits to the cell
surface, revealed overall decreased signal intensityfor both of these proteins compared with healthy
control tissues (Figure 5), agreeing with previous
studies that showed decreased expression of these
proteins in ARVC (27). Additionally, staining for
GSK3b revealed that this protein retained its cyto-
plasmic distribution and did not translocate to the
intercalated discs, which has been shown previously
to occur in classical ARVC (28). Last, staining for the
desmosomal protein plakoglobin and the major car-
diac gap junction protein Cx43 (normally located in
the intercalated discs) revealed these proteins to have
immunoreactive signals similar in intensity and dis-
tribution to the healthy control tissues, although the
expression of these proteins is usually reduced at
cardiac cell–cell junctions in classical ARVC (26,27).
Immunohistochemical staining of FLNC revealed no
signiﬁcant intracellular protein aggregates in cardiac
myocytes (Figure 6).
Desmosomal and gap junction protein abnormal-
ities have similarly been previously reported in the
FIGURE 5 Immunohistochemistry of Left Ventricular Myocardial Tissue
Immunostaining of the explanted heart of patient DNFDC057-II:2 carrying the G1891Vfs61X FLNC truncation. (A) Immunoreactive signals for plakoglobin and connexin
43 (Cx43) at intercalated discs are normal compared with control samples, whereas junctional signal for desmoplakin is reduced. N-cadherin is used as a tissue quality
control and is normal in all samples. (B) SAP97 signal is depressed compared with control samples. GSK3b maintained its normal cytoplasmic distribution.
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us to also perform immunostaining of buccal mucosa
smears obtained from affected patients DNFDC057
II:1 and II:2 (Figure 7). Our buccal mucosa cell staining
results were generally concordant with the LV
myocardial immunostaining of patient II:2, including
diminished signal intensity for desmoplakin and
SAP97, and signal intensity near normal levels for
plakoglobin. However, unlike the normal levels of
Cx43 observed in the LV myocardial immunostaining,
staining for Cx43 was found to be reduced in the
buccal mucosa cells.FIGURE 6 FLNC in Cardiac Tissue
Immunohistochemical staining of FLNC does not show signiﬁcant presen
reduced amount of FLNC protein compared with control subjects (A andDISCUSSION
In a cohort of 319 DCM families, prospectively enrolled
in the Familial Cardiomyopathy Research Registry at
the University of Colorado Hospital and Azienda
Sanitaria Universitaria Integrata of Trieste Hospital,
we identiﬁed 7 families (2.2%) harboring 6 different
FLNC truncation variants distributed across the FLNC
gene. These truncation carriers had a prominent
arrhythmogenic phenotype characteristic of arrhyth-
mogenic DCM, family history of SCD, frequent RV
involvement, and displayed no clinical signs ofce of aggregates in cardiomyocytes, and the weaker staining in the patient (C) suggests a
B), as previously shown by western blot (9).
FIGURE 7 Immunohistochemistry of Buccal Mucosa
Immunostaining of the buccal mucosa in patients DNFDC057-II:1 and II:2 shows normal signals for plakoglobin, and diminished signal for
connexin 43 (Cx43), desmoplakin, and SAP97. E-cadherin staining is used as a cell quality control and is normal in all samples.
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512skeletal muscle involvement. As we previously re-
ported, arrhythmogenic DCM patients have a higher
risk for life-threatening ventricular arrhythmias and
SCD, in particular when a family history of SCD is pre-
sent, highlighting the importance of early identiﬁca-
tion of patients carrying FLNC truncation variants (13).
Filamins are large cytoskeletal actin cross-linking
proteins that stabilize the actin ﬁlament networks
and link them to the cell membrane by binding
transmembrane proteins and ion channels (29).
FLNC encodes a large protein (2,725 amino acids)
primarily expressed in the cardiac and skeletal
muscle that interacts with sarcomeric proteins in the
Z-disc and the sarcolemma (6). Mutations in FLNC
were initially reported to cause MFM (6), while car-
diac involvement may have been noted, but not
studied extensively. A study of German families with
the p.Trp2710* founder mutation reported that 8 of
31 patients had LV hypertrophy, atrial ﬂutter, and
right bundle branch block (30). More recent reports
support FLNC involvement in a spectrum of cardio-
myopathies, including HCM, RCM, and DCM, where
arrhythmias, cardiac conduction disease, and SCD
were also described (7,8) in the absence of skeletal
muscle pathology (7–12). Similarly, our FLNC trun-
cation carriers also exhibited no clinical evidence of
skeletal muscle abnormalities. Our current reportprovides additional evidence of an arrhythmogenic
DCM phenotype likely caused by FLNC truncation
variants, including LV dysfunction, RV involvement,
severe arrhythmias, and conduction disease.
All variants identiﬁed in our study are expected to
lead to a truncated or absent FLNC protein. Our anal-
ysis of FLNC transcripts revealed that most (87.0%)
were wildtype, suggestive of a haploinsufﬁciency
model. This agrees with our previous investigation
reporting that explanted heart tissue from a FLNC
truncation carrier had reduced levels of FLNC protein
compared with healthy control samples by Western
blot, lending support for a haploinsufﬁciency mecha-
nism of FLNC pathology (9). We also previously found
that a reduction in ﬂncb (ortholog of human FLNC)
RNA expression in zebraﬁsh results in structural and
functional cardiac abnormalities (9), further support-
ing the theory that reduced FLNC expression may
result in the observed cardiac dysfunctions.
We additionally found irregular and thickened
Z-discs in the tissue of FLNC truncation carriers
(Figures 4A to 4D). Similarly, in our ﬂncb MO knock-
down zebraﬁsh model, the cardiac muscle ultrastruc-
ture displayed prominent Z-disc disarray and
malformations, and in some instances the Z-disc was
absent (9). Surprisingly, our current study did not ﬁnd
cytoplasmic protein aggregates in the heart, which
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513have been described previously in FLNC-associated
patients with MFM (in muscle biopsies) as well as HCM
and RCM patients (7,8). In these cases, accumulations
of protein aggregates are believed to result from the
inability of FLNC to dimerize and cross-link with actin
at the C-terminal end of FLNC. The absence of FLNC
protein aggregates in our study and in the series of
Ortiz-Genga et al. (12), is again more in line with a
haploinsufﬁciency model.
The highly arrhythmogenic phenotype and the
pattern of biventricular subepicardial ﬁbrosis and
fatty inﬁltration seen in 2 siblings from family
DNFDC057 is more reminiscent of features previously
described speciﬁcally in left-dominant arrhythmo-
genic cardiomyopathy and PLN R14del cardiomyop-
athy (31) rather than classical ARVC. For example,
reduced junctional signal for desmoplakin, seen in
both the heart and buccal mucosa in siblings from
family DNFDC057, is more closely linked with biven-
tricular involvement. Similarly, changes in the dis-
tribution of cell–cell junction proteins in the heart
and buccal mucosa of these patients are more typical
of left-dominant arrhythmogenic cardiomyopathy
than classical ARVC. Interestingly, we also observed
reduced signal for the membrane-associated guany-
late kinase protein SAP97 in both the heart and buccal
mucosa in 2 siblings from kindred DNFDC057. Such
reduced SAP97 signal has been implicated in
abnormal trafﬁcking of ion channel proteins involved
in channeling sodium and potassium ions, speciﬁcally
related to regulating the INa, and IK1 currents, which
help maintain normal cardiac ventricular resting
membrane action potential (27). This may be relevant
to the highly arrhythmogenic phenotype seen in our
patients: reduced junctional signals for plakoglobin
and Cx43 and translocation of GSK3b to cell–cell
junctions are all features consistently seen in classical
ARVC, but were not seen in our patients. Finally,
although we have previously shown that buccal mu-
cosa cells exhibit changes similar to those seen in the
hearts of ARVC patients (24), studies here are the ﬁrst
to directly compare buccal cells and myocardium
from the same patients. These results add further
credence to the idea that changes in the heart of
complex familial arrhythmia syndromes may also be
seen in the buccal mucosa.
STUDY LIMITATIONS. Our study may be limited by
the low frequency of FLNC truncations, the inability
to perform extensive segregation analysis due to
small family sizes, and an incomplete availability of
DNA samples from biological members of FLNC
truncation families. Efforts to recruit additional
family members, especially reportedly affectedindividuals, have not been fruitful to date. In addi-
tion, cardiac tissue was only available from 1 family
(2 siblings), which hinders our ability to systemati-
cally evaluate the effects of different variants on
cardiac cellular structure and function. The presence
of a variant in another DCM-related gene (SCN5A) in
combination with the FLNC truncation variant in pa-
tient TSFDC043 I:1 presents an additional confound-
ing variable. Although all patients are routinely
examined for muscle wasting, rigidity, muscle
strength, and coordination, invasive skeletal muscle
studies that may reveal more subtle pathology, such
as electromyography and muscle biopsy, were not
performed. Additional phenotypic characterization,
such as with contrast-enhanced cardiac magnetic
resonance, was also not done in our population.
Finally, future studies are needed to elucidate how
FLNC truncation variants lead to cardiomyocyte
dysfunction and cardiac muscle disease.
CONCLUSIONS
Our report provides new evidence that FLNC trunca-
tion variants are associated with a severe arrhyth-
mogenic DCM phenotype in the absence of overt
skeletal muscle disease. FLNC should be included in
DCM genetic testing panels, particularly when
arrhythmias complicate the presenting phenotype.
Additionally, patients with FLNC truncation variants
should be clinically monitored for arrhythmias
and considered for implantable cardioverter-
deﬁbrillators. Histological and ultrastructural anal-
ysis of heart muscle showed no protein aggregates as
described in MFM, but instead showed biventricular
subepicardial ﬁbrofatty inﬁltration, Z-disc abnormal-
ities, and redistribution of cell–cell junction proteins.
We theorize that haploinsufﬁciency of FLNC (9) may
disrupt its normal functions of cross-linking actin
ﬁlaments, connecting subsarcolemmal sarcomere
Z-discs to the cell membrane and integrins, and con-
necting actin to cell–cell adhesion junctions in inter-
calated discs, to result in interference with the
desmosomal/cell–cell junction pathway and manifest
as a phenotypically arrhythmogenic cardiomyopathy.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: As the
number of genes associated with DCM continues to in-
crease, differences in clinical presentations are becoming
recognized. Patients with FLNC truncation variants should
be clinically monitored for arrhythmias and considered for
implantable cardioverter-deﬁbrillator devices.
TRANSLATIONAL OUTLOOK: DCM is a common cause
of heart failure and life-threatening arrhythmias, and it is
frequently caused by gene mutations. The whole spec-
trum of genetic determinants of DCM is still unknown:
however, recently, a novel disease gene known to cause
muscular dystrophy, ﬁlamin C, has been reported in hu-
man dilated cardiomyopathy and zebraﬁsh models. Here,
we report that FLNC truncating variants are not rare, are
associated with a cardiac-restricted phenotype, are char-
acterized by a high risk of life-threatening ventricular
arrhythmias, and are a pathological cellular phenotype
affecting the cell–cell adhesion structures, which partially
overlaps with ARVC.
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